How to Discover Novel Complex Proteins Faster
LenioBio and Danish startup AffinityAI combine AI-powered protein design with high-throughput cell-free expression platform
Advertisement
LenioBio GmbH announced a strategic partnership with AffinityAI, a Danish start-up pioneering AI-driven protein design. This collaboration combines LenioBio’s proprietary cell-free protein expression platform, ALiCE®, with AffinityAI’s advanced design engine, Designerbodies™, to significantly accelerate the discovery and optimization de novo proteins.
By integrating AI-guided protein design with high-throughput cell-free expression, the partnership closes the traditional “lab-in-loop” gap, enabling design, testing, and feedback cycles to be completed in days rather than weeks. AffinityAI’s computational pipeline rapidly generate and refine novel protein sequences, while LenioBio’s ALiCE® platform enables immediate expression and scalable production without the limitations of living cells. This synergy enables faster screening, iterative optimization, and expression of even the most challenging proteins.
“We have reinvented cell-free protein expression to fully harness the power of AI-driven protein design”, said André Goerke, CEO of LenioBio. “ALiCE® combines the openness and flexibility of a cell-free system with the scalability of cell-based platforms. Together with AffinityAI, we can accelerate discovery cycles and bring precision-designed protein therapeutics to development much faster.”
AffinityAI specializes in the in-silico design of high-affinity, stable binding proteins called Designerbodies™. Unlike conventional antibodies, Designerbodies™ are designed with predefined binding sites, offering superior precision and control. These designs will be rapidly screened and optimized using ALiCE®, creating an automated, high-throughput pipeline for next-generation protein products for drug development, diagnostics, and biomedical research.
“LenioBio’s ALiCE® system perfectly complements our AI-based approach”, said Timothy P. Jenkins, PhD, Head of Data Science and Associate Professor at DTU Bioengineering and CEO of AffinityAI. “Together, we can deliver Designerbodies™ faster, at higher throughput, and with greater precision than ever before.”
This collaboration marks a significant step forward in accelerating the development of novel protein therapeutics, combining cutting-edge AI design with scalable, cell-free expression technology.
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.